Raptor Pharmaceutical Corp.  

(Public, NASDAQ:RPTP)   Watch this stock  
Find more results for William M. Daley
10.78
+0.08 (0.75%)
After Hours: 10.78 0.00 (0.00%)
Oct 20, 5:02PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.36 - 10.89
52 week 7.12 - 17.72
Open 10.54
Vol / Avg. 0.00/675,327.00
Mkt cap 671.35M
P/E     -
Div/yield     -
EPS -0.93
Shares 62.74M
Beta -0.34
Inst. own 50%
Nov 6, 2014
Q3 2014 Raptor Pharmaceutical Corp Earnings Release (Tentative) - 4:00PM EST - Add to calendar
Oct 20, 2014
Raptor Pharmaceutical Corp at Maxim Group's Huntington's Disease & Related Movement Disorders Workshop & Roundtable
Sep 10, 2014
Raptor Pharmaceutical Corp at Morgan Stanley Healthcare Conference
Aug 13, 2014
Raptor Pharmaceutical Corp at Canaccord Genuity Growth Conference
Aug 7, 2014
Q2 2014 Raptor Pharmaceutical Corp Earnings Call
Aug 7, 2014
Q2 2014 Raptor Pharmaceutical Corp. Earnings Release
Jul 29, 2014
Raptor Pharmaceutical Corp Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -77.81% -411.43%
Operating margin -55.69% -307.65%
EBITD margin - -305.06%
Return on average assets -54.05% -78.50%
Return on average equity -229.20% -286.17%
Employees 70 -
CDP Score - -

Address

7 Hamilton Lndg Ste 100
NOVATO, CA 94949-8246
United States - Map
+1-415-4086200 (Phone)
+1-415-3828002 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Raptor Pharmaceuticals Corp. (RPC), formerly TorreyPines Therapeutics, Inc., is an early development-stage Company. The Company�s product portfolio includes both candidates from its drug targeting platforms and in-licensed and acquired product candidates. As of August 31, 2010, its pipeline includes three clinical development programs. It also has three other clinical-stage product candidates, for which it is seeking business development partners, and it has four preclinical product candidates it is developing, three of which are based upon its drug-targeting platforms. As of August 31, 2010, the Company had no revenues. On September 29, 2009, the Company and its wholly owned subsidiary, ECP Acquisition, Inc., completed a reverse merger, business combination with RPC, pursuant to which RPC became its wholly owned subsidiary.

Officers and directors

Llew Keltner M.D., Ph.D. Independent Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Julie Anne Smith President, Chief Executive Officer Designate, Director
Age: 43
Bio & Compensation  - Reuters
Christopher M. Starr Ph.D. Director
Age: 61
Bio & Compensation  - Reuters
Georgia L. Erbez Chief Financial Officer, Treasurer, Secretary
Age: 47
Bio & Compensation  - Reuters
Robert H. Uhl Managing Director
Bio & Compensation  - Reuters
Thomas E. Daley Chief Business Officer
Age: 51
Bio & Compensation  - Reuters
Raymond William Anderson Independent Director
Age: 72
Bio & Compensation  - Reuters
Suzanne L. Bruhn Ph.D. Independent Director
Age: 50
Bio & Compensation  - Reuters
Richard L. Franklin M.D., Ph.D. Independent Director
Age: 68
Bio & Compensation  - Reuters
Erich Sager Independent Director
Age: 56
Bio & Compensation  - Reuters